Fig. 1: Immunohistochemistry of breast carcinoma clinical specimens. | Cell Death & Disease

Fig. 1: Immunohistochemistry of breast carcinoma clinical specimens.

From: IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells

Fig. 1

A TNBC tissue specimens were stained with anti-human IL-26 mAb (n = 19). All immunohistochemistry specimens were counterstained with hematoxylin. A representative image of the TNBC case with high IL-26 protein expression was shown. Original magnification, ×100. Scale bar, 50 μm. B Each subtype of breast carcinoma tissue specimen was stained with anti-human IL-26 mAb (TNBC (n = 19), HER2 (n = 20), and Luminal (n = 23)). IL-26 in cytoplasm staining of stromal immune cells was determined semi-quantitatively in 10% increments. The percentage of IL-26-positive stromal immune cells in each subtype of breast carcinoma is shown. *p < 0.05. C TNBC tissue specimens (the same case as shown in A) were double-stained with IL-26 (brown) plus CD4, CD8, CD68, or CD163 (blue), respectively. All tissue sections were counterstained with hematoxylin. IL-26 was merged with cell surface CD4, CD68, and CD163 (arrows in each panel). Original magnification, ×40. Scale bar, 25 μm.

Back to article page